Status:
TERMINATED
A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purposes of this study are: * To determine the maximum tolerated dose (MTD) of SAHA administered every 12 hours for 14 consecutive days followed by 7 days of rest during the first two cycles (i.e...
Eligibility Criteria
Inclusion
- Adult patients with refractory or relapsed multiple myeloma, ECOG performance status 0-2 (ECOG)
- Adequate bone marrow reserve
- Adequate hepatic and renal function
- Ability to swallow capsules
- 3 weeks or more from prior chemotherapy and have recovered from prior toxicities
Exclusion
- Patients who plan to go for bone marrow transplant within 4 weeks of start of treatment
- Patients with prior treatment with other investigational agents with a similar anti-tumor mechanism
- Patients with other active/uncontrolled clinically significant illnesses
- Pregnant or nursing female patients
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
End Date :
February 14 2006
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00109109
Start Date
December 1 2003
End Date
February 14 2006
Last Update
November 14 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.